Australia restricts AstraZeneca’s vaccine rollout, to get third COVID-19 vaccine shortly

Source: Juan Roballo, Shutterstock

Summary

  • Australia’s cabinet to discuss border closure considering new guidance regarding the AstraZeneca vaccine.
  • The country had ordered almost 20 million shots of Pfizer-BioNTech’s COVID-19 vaccine.
  • Healthcare individuals under 50 years expected to get the AstraZeneca’s vaccine will now receive the Pfizer-BioNTech’s vaccine.
  • Australia could have the Novavax vaccine as a third COVID-19 vaccine in the future.

Australia’s cabinet will have discussions around the reopening on Friday, considering the new guidance for Oxford-AstraZeneca’s vaccine. Paul Kelly, Chief Medical Officer Australia, stated that the Australian PM Scott Morrison and other state & territory leaders would discuss border closure concerns.

Mr Morrison had earlier stated that the policy shift would further delay Australia’s vaccination plans, already affected by the supply shortage. This shift was based on the possible links found between AstraZeneca Plc’s (LON:AZN) COVID-19 vaccine and rare cases of blood coagulation.

Australia had ordered almost 20 million shots of Pfizer Inc (NYSE:PFE) - BioNTech SE’s (NASDAQ:BNTX) COVID-19 vaccine. The country is confident this would be sufficient for 10 million people (total population: ~26 million). The nation was banking on AstraZeneca jab for the majority, with Australian biotech giant CSL Limited (ASX:CSL) contracted to manufacture 50 million doses in Australia.

Source: © Serazahmed99 | Megapixl

DO READ: Here is what you shouldn’t miss about CSL Limited (ASX:CSL)

Australia restricts the use of AstraZeneca’s vaccine

Australia is one of the latest nations to restrict AstraZeneca vaccine’s use by recommending that it will not be administered to individuals under 50 years.

The country announced this after the drug regulators conducted a series of urgent meetings. These meetings followed advice from the European Medicines Agency (EMA) that it had discovered a potential link between AstraZeneca’s vaccine and rare blood clots. Moreover, several European nations have already banned AstraZeneca's jab for younger people.

PM Morrison has received several recommendations related to the use of Pfizer-BioNTech’s COVID-19 vaccine in people aged under 50 years.

On immunisation, the Australian Technical Advisory Group recommended that people under 50 who had already received the first dose of AstraZeneca’s vaccine should take their second shot, as according to the medical advice, the rare blood coagulations were only seen after the first dose.

Moreover, healthcare people under 50 years who were anticipated to get AstraZeneca’s shot will now be administered the Pfizer-BioNTech’s vaccine. This will likely delay the vaccination program of Australia.

ALSO READ: Pfizer-BioNTech’s COVID-19 vaccine shows 100% efficacy in young adolescents

Australia to get 3rd potential COVID-19 vaccine

The country could potentially get another vaccine in the future from Novavax. Australia has already signed a contract with the US-based Company to receive approximately 51 million doses. Novavax COVID-19 vaccine’s interim data demonstrated 96% efficacy against the original variant, 86.3% against the UK strain, and 48.6% against the South African variant of coronavirus.

Source: Copyright © 2021 Kalkine Media Pty Ltd

Several media reports highlighted that if Novavax vaccine data from the ongoing Phase 3 clinical trials is encouraging, it will get Therapeutic Goods Administration’s (TGA) approval.

Furthermore, biotech behemoth CSL stated that the Company would consider its capacity to manufacture Novavax’s product but only after completing AstraZeneca’s vaccine doses.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK